search
Back to results

Combining VNS With PT Interventions for Individuals With PD (VNS-PT-PD)

Primary Purpose

Parkinson Disease

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
taVNS
Exercise
Sponsored by
University of Alabama at Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring Parkinson's Disease, Exercise, Vagus Nerve Stimulation, VNS, taVNS

Eligibility Criteria

35 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: age between 35 and 80 years no walking aids stable medication 4 weeks prior to and during the study no falls in the past 6 months participant must have MD who is willing to provide oversight and approval for clinically defined "off" state Exclusion Criteria: mild cognitive impairment (MoCA <25) self reported depression antidepressive or antipsychotic medication participation in a VNS study in the past year disabling bradykinesia to ensure patients are able to participate in intensive physiotherapy (based on clinical impression and in accordance to UPDRS part III item 14 - to be administered in clinic) prior history of cardiovascular, neurological or musculoskeletal disorders known to interfere with testing PD features implanted medical device of any type history of seizures peripheral neuropathy including temporal mandibular disorders and Bells Palsy, and vasovagal syncope.

Sites / Locations

  • WHARFRecruiting
  • UABRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

active taVNS + exercise

sham taVNS + exercise

Arm Description

Participants who are randomized into the active taVNS + exercise group will receive 15 minutes of active taVNS prior to exercise sessions.

Participants who are randomized into the sham taVNS + exercise group will receive 0 mA of current for 15 minutes prior to exercise sessions.

Outcomes

Primary Outcome Measures

MDS-UPDRS Part III
In our study, we will utilize the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III. This scale, widely used in the clinical and research settings, helps us evaluate the motor symptoms of Parkinson's Disease. The MDS-UPDRS Part III scale ranges from 0 to 132, with 0 representing no motor symptoms and 132 representing severe motor symptoms. Therefore, a higher score on the MDS-UPDRS Part III scale indicates a worse outcome, reflecting more severe motor symptoms associated with Parkinson's disease.
6MWT
6-Minute Walk Test (6MWT): We utilize the 6-Minute Walk Test in our study to evaluate the functional exercise capacity of our participants. The 6MWT involves participants walking as far as they can in a span of six minutes on a flat, hard surface. The total distance covered in six minutes is recorded as the score. In this test, a greater distance indicates better physical endurance and mobility. Therefore, in our study, a higher score (greater distance walked) on the 6MWT represents a better outcome, signifying superior functional exercise capacity.
10MWT
The 10MWT is a timed walking test commonly used in clinical and research settings to assess an individual's gait speed and functional mobility. It measures the time it takes for a person to walk a distance of 10 meters (approximately 33 feet). The scale title, in this case, is the time in seconds or minutes required to complete the 10-meter walk. There are no specific minimum and maximum values for this measure since it depends on the individual's walking ability. However, lower scores (i.e., shorter times) generally indicate better outcomes, as they reflect faster gait speed and improved mobility. Conversely, higher scores (longer times) would suggest slower walking speed and potentially poorer functional mobility.
Mini-Best Test
The Mini-Balance Evaluation Systems Test (Mini-BESTest) is a clinical assessment tool used to evaluate a person's balance and stability. It consists of 14 items that assess different aspects of balance, including anticipatory postural adjustments, reactive postural control, sensory orientation, dynamic gait, and stability during functional tasks. The scale title for the Mini-BESTest is the total score, which ranges from 0 to 28. Higher scores on the Mini-BESTest indicate better balance performance and greater overall stability. A score of 28 represents the best possible outcome, indicating excellent balance abilities across all assessed domains. Conversely, lower scores indicate poorer balance control and increased risk of falls.
FGA
The Functional Gait Assessment (FGA) is a clinical measure used to assess an individual's walking ability and functional mobility. It evaluates various aspects of gait, including balance, coordination, range of motion, and adaptability. The FGA consists of 10 different tasks or conditions that challenge the person's walking abilities in different ways, such as walking while turning, walking over obstacles, or walking with eyes closed. The scale title for the FGA is the total score, which ranges from 0 to 30. Higher scores on the FGA indicate better functional gait performance and greater walking independence. A score of 30 represents the best possible outcome, reflecting excellent gait function across all assessed conditions. Conversely, lower scores suggest impaired gait function and reduced functional mobility.
mCTSIB
The modified Clinical Test of Sensory Interaction on Balance (mCTSIB) is a diagnostic tool used to evaluate an individual's sensory integration and balance control. It assesses the person's ability to maintain balance under various sensory conditions. The mCTSIB involves four different standing positions, each with different sensory inputs: (1) feet together on a firm surface with eyes open, (2) feet together on a firm surface with eyes closed, (3) feet together on a foam surface with eyes open, and (4) feet together on a foam surface with eyes closed. The scale title for the mCTSIB is the overall balance score, typically ranging from 0 to 24. Higher scores on the mCTSIB indicate better balance control and greater sensory integration. A score of 24 represents the best possible outcome, indicating excellent balance performance across all tested conditions. Conversely, lower scores suggest impaired balance control and decreased sensory integration abilities.

Secondary Outcome Measures

MoCA
The Montreal Cognitive Assessment (MoCA) is a widely accepted tool in both clinical and research settings, allowing us to evaluate cognitive abilities, specifically focusing on attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The MoCA scale ranges from 0 to 30, with a score of 30 indicating the highest level of cognitive function. Lower scores on the MoCA suggest a higher level of cognitive impairment. Therefore, in the context of our study, a higher score on the MoCA represents a better outcome, signifying superior cognitive performance.
DKEFS Color Word Interference Test
Delis-Kaplan Executive Function System (D-KEFS) Color Word Interference Test is used to assess cognitive flexibility and inhibitory control. It includes conditions like "Color Naming," "Word Reading," "Inhibition," and "Inhibition/Switching." Higher scores indicate better performance, reflecting superior cognitive flexibility and inhibitory control.
HVLT
The Hopkins Verbal Learning Test (HVLT) evaluates verbal learning and memory abilities. It involves three learning trials where a list of 12 words is presented, followed by recall. After a delay, a recognition trial is conducted with 24 words, including the original 12 and distractors. Scale titles include Total Recall (total words recalled), Delayed Recall (words recalled after a delay), and Recognition Discrimination (identifying learned words). Higher scores indicate better verbal learning, memory, and recognition abilities.
DST
Measure of cognitive function
DSST
The Digit Span Test (DST) is a neuropsychological assessment tool used to evaluate an individual's working memory and attention span. It measures the person's ability to temporarily hold and manipulate a series of digits in their memory. The DST typically consists of two components: forward digit span and backward digit span. In the forward digit span, the examiner reads a series of digits aloud, and the individual is required to repeat them back in the same order. In the backward digit span, the individual is asked to recall the digits in reverse order. The scale title for the DST is the maximum digit span achieved in each component (forward and backward). The minimum value for both components is typically two, as the test starts with a two-digit sequence, and the maximum value varies depending on the test version and administration protocol. Higher digit spans indicate better working memory capacity and attentional abilities.
N-back
The N-back task assesses working memory and attention. Participants match current stimuli with those presented "N" steps back. Higher "N" values increase task difficulty. Performance is measured by accuracy and reaction time. Higher accuracy and faster reactions indicate better working memory and attention abilities. Scale title varies but reflects accuracy and reaction time on the N-back task.
Promise Neuro-QOL
The Patient Reported Outcomes Measurement Information System (PROMIS) Quality of Life in Neurological Disorders (Neuro-QoL) measurement system assesses health-related quality of life in neurological conditions. It includes questionnaires measuring physical function, mobility, emotional well-being, fatigue, social participation, and cognitive function. Scale titles vary by domain. Higher scores indicate better outcomes. T-scores facilitate interpretation and comparison. PROMIS Neuro-QOL provides insights for clinicians and researchers, addressing challenges in different functional domains of neurological conditions.
SF-36
The SF-36 is a self-reported questionnaire measuring health-related quality of life. It assesses dimensions like physical functioning, role limitations, pain, general health, vitality, social functioning, and mental health. It provides scores for each dimension and summary scores (PCS and MCS) for overall physical and mental health. Scale titles reflect specific dimensions. Scores range from 0 to 100, with higher scores indicating better health-related quality of life. SF-36 offers a comprehensive assessment of perceived health status and well-being.
DKEFS Trails Making Test (Trails)
Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test (Trails) measures visual attention and task-switching abilities. Part A involves connecting numbered circles, and Part B requires switching between numbers and letters. Completion time is the basis for scoring, with shorter times indicating better performance in visual attention and task-switching.
DKEFS Verbal Learning Test (VLT)
Delis-Kaplan Executive Function System (D-KEFS) Verbal Learning Test (VLT) evaluates verbal memory capabilities. Participants recall words across multiple trials, and the score is based on the number of correctly recalled words. Higher scores indicate superior verbal memory performance.

Full Information

First Posted
May 12, 2023
Last Updated
September 18, 2023
Sponsor
University of Alabama at Birmingham
search

1. Study Identification

Unique Protocol Identification Number
NCT05871151
Brief Title
Combining VNS With PT Interventions for Individuals With PD
Acronym
VNS-PT-PD
Official Title
Combining Trans-auricular Vagus Nerve Stimulation With Physical Therapy Interventions for Individuals With Parkinson's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2023 (Actual)
Primary Completion Date
August 31, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the combined effects of non-invasive neuromodulation (specifically transauricular Vagus Nerve Stimulation) with exercise interventions to improve physical function and quality of life in individuals with Parkinson's Disease.
Detailed Description
During this clinical trial, participants will be randomized into two groups, with half of the participants assigned to GROUP 1: active taVNS + exercise, and half of the participants assigned to GROUP 2: sham taVNS + exercise. The active taVNS + exercise group will receive 15 minutes of active taVNS prior to treatment. Participants who are randomized into the sham taVNS + exercise group will receive 0 mA of current for 15 minutes prior to treatment. All participants will be guided through exercises by an exercise specialist, which will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations; 3) a home program, which consists of exercises and tasks that the patient can do on their own and performed nightly, and 4) group yoga sessions. The exercise intervention proposed involves the supervision of a trained exercise specialist at all times during the treatment session. Exercise will be provided in a clinical setting, 60 minutes per session, up to 3 sessions/week, for 4 weeks total.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
Keywords
Parkinson's Disease, Exercise, Vagus Nerve Stimulation, VNS, taVNS

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Trial with two parallel groups
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Participants will receive either active or sham taVNS + exercise, but they will not be aware of whether they are receiving the active treatment or the sham treatment. The care provider who administers the exercise intervention will also be blinded to the treatment assignment and will not know whether the participant received active or sham treatment. Additionally, the investigator who assesses the outcomes (e.g., changes in MDS-UPDRS, physical activity levels, cognitive function, and quality of life) will also be blinded to the treatment assignment and will not know whether the participant received the active or sham treatment.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
active taVNS + exercise
Arm Type
Experimental
Arm Description
Participants who are randomized into the active taVNS + exercise group will receive 15 minutes of active taVNS prior to exercise sessions.
Arm Title
sham taVNS + exercise
Arm Type
Sham Comparator
Arm Description
Participants who are randomized into the sham taVNS + exercise group will receive 0 mA of current for 15 minutes prior to exercise sessions.
Intervention Type
Device
Intervention Name(s)
taVNS
Intervention Description
Trans-auricular Vagus Nerve Stimulation is a non-invasive method of stimulating the auricular branch of the vagus nerve through the inner ear. Trans-auricular Vagus Nerve Stimulation will be provided using a commercially available device. The investigators will use custom earbuds that will make the experience significantly more comfortable than traditional transauricular Vagus Nerve Stimulation.
Intervention Type
Behavioral
Intervention Name(s)
Exercise
Intervention Description
All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations; 3) a home program, which consists of exercises and tasks that the patient can do on their own and performed nightly; and 4) group exercise sessions. The exercise intervention proposed involves the supervision of a trained exercise specialist at all times during the treatment session. Exercise will be provided in a clinical setting, 60 minutes per session, up to 3 sessions/week, for 4 weeks total.
Primary Outcome Measure Information:
Title
MDS-UPDRS Part III
Description
In our study, we will utilize the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III. This scale, widely used in the clinical and research settings, helps us evaluate the motor symptoms of Parkinson's Disease. The MDS-UPDRS Part III scale ranges from 0 to 132, with 0 representing no motor symptoms and 132 representing severe motor symptoms. Therefore, a higher score on the MDS-UPDRS Part III scale indicates a worse outcome, reflecting more severe motor symptoms associated with Parkinson's disease.
Time Frame
8 weeks
Title
6MWT
Description
6-Minute Walk Test (6MWT): We utilize the 6-Minute Walk Test in our study to evaluate the functional exercise capacity of our participants. The 6MWT involves participants walking as far as they can in a span of six minutes on a flat, hard surface. The total distance covered in six minutes is recorded as the score. In this test, a greater distance indicates better physical endurance and mobility. Therefore, in our study, a higher score (greater distance walked) on the 6MWT represents a better outcome, signifying superior functional exercise capacity.
Time Frame
8 weeks
Title
10MWT
Description
The 10MWT is a timed walking test commonly used in clinical and research settings to assess an individual's gait speed and functional mobility. It measures the time it takes for a person to walk a distance of 10 meters (approximately 33 feet). The scale title, in this case, is the time in seconds or minutes required to complete the 10-meter walk. There are no specific minimum and maximum values for this measure since it depends on the individual's walking ability. However, lower scores (i.e., shorter times) generally indicate better outcomes, as they reflect faster gait speed and improved mobility. Conversely, higher scores (longer times) would suggest slower walking speed and potentially poorer functional mobility.
Time Frame
8 weeks
Title
Mini-Best Test
Description
The Mini-Balance Evaluation Systems Test (Mini-BESTest) is a clinical assessment tool used to evaluate a person's balance and stability. It consists of 14 items that assess different aspects of balance, including anticipatory postural adjustments, reactive postural control, sensory orientation, dynamic gait, and stability during functional tasks. The scale title for the Mini-BESTest is the total score, which ranges from 0 to 28. Higher scores on the Mini-BESTest indicate better balance performance and greater overall stability. A score of 28 represents the best possible outcome, indicating excellent balance abilities across all assessed domains. Conversely, lower scores indicate poorer balance control and increased risk of falls.
Time Frame
8 weeks
Title
FGA
Description
The Functional Gait Assessment (FGA) is a clinical measure used to assess an individual's walking ability and functional mobility. It evaluates various aspects of gait, including balance, coordination, range of motion, and adaptability. The FGA consists of 10 different tasks or conditions that challenge the person's walking abilities in different ways, such as walking while turning, walking over obstacles, or walking with eyes closed. The scale title for the FGA is the total score, which ranges from 0 to 30. Higher scores on the FGA indicate better functional gait performance and greater walking independence. A score of 30 represents the best possible outcome, reflecting excellent gait function across all assessed conditions. Conversely, lower scores suggest impaired gait function and reduced functional mobility.
Time Frame
8 weeks
Title
mCTSIB
Description
The modified Clinical Test of Sensory Interaction on Balance (mCTSIB) is a diagnostic tool used to evaluate an individual's sensory integration and balance control. It assesses the person's ability to maintain balance under various sensory conditions. The mCTSIB involves four different standing positions, each with different sensory inputs: (1) feet together on a firm surface with eyes open, (2) feet together on a firm surface with eyes closed, (3) feet together on a foam surface with eyes open, and (4) feet together on a foam surface with eyes closed. The scale title for the mCTSIB is the overall balance score, typically ranging from 0 to 24. Higher scores on the mCTSIB indicate better balance control and greater sensory integration. A score of 24 represents the best possible outcome, indicating excellent balance performance across all tested conditions. Conversely, lower scores suggest impaired balance control and decreased sensory integration abilities.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
MoCA
Description
The Montreal Cognitive Assessment (MoCA) is a widely accepted tool in both clinical and research settings, allowing us to evaluate cognitive abilities, specifically focusing on attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The MoCA scale ranges from 0 to 30, with a score of 30 indicating the highest level of cognitive function. Lower scores on the MoCA suggest a higher level of cognitive impairment. Therefore, in the context of our study, a higher score on the MoCA represents a better outcome, signifying superior cognitive performance.
Time Frame
8 weeks
Title
DKEFS Color Word Interference Test
Description
Delis-Kaplan Executive Function System (D-KEFS) Color Word Interference Test is used to assess cognitive flexibility and inhibitory control. It includes conditions like "Color Naming," "Word Reading," "Inhibition," and "Inhibition/Switching." Higher scores indicate better performance, reflecting superior cognitive flexibility and inhibitory control.
Time Frame
8 weeks
Title
HVLT
Description
The Hopkins Verbal Learning Test (HVLT) evaluates verbal learning and memory abilities. It involves three learning trials where a list of 12 words is presented, followed by recall. After a delay, a recognition trial is conducted with 24 words, including the original 12 and distractors. Scale titles include Total Recall (total words recalled), Delayed Recall (words recalled after a delay), and Recognition Discrimination (identifying learned words). Higher scores indicate better verbal learning, memory, and recognition abilities.
Time Frame
8 weeks
Title
DST
Description
Measure of cognitive function
Time Frame
8 weeks
Title
DSST
Description
The Digit Span Test (DST) is a neuropsychological assessment tool used to evaluate an individual's working memory and attention span. It measures the person's ability to temporarily hold and manipulate a series of digits in their memory. The DST typically consists of two components: forward digit span and backward digit span. In the forward digit span, the examiner reads a series of digits aloud, and the individual is required to repeat them back in the same order. In the backward digit span, the individual is asked to recall the digits in reverse order. The scale title for the DST is the maximum digit span achieved in each component (forward and backward). The minimum value for both components is typically two, as the test starts with a two-digit sequence, and the maximum value varies depending on the test version and administration protocol. Higher digit spans indicate better working memory capacity and attentional abilities.
Time Frame
8 weeks
Title
N-back
Description
The N-back task assesses working memory and attention. Participants match current stimuli with those presented "N" steps back. Higher "N" values increase task difficulty. Performance is measured by accuracy and reaction time. Higher accuracy and faster reactions indicate better working memory and attention abilities. Scale title varies but reflects accuracy and reaction time on the N-back task.
Time Frame
8 weeks
Title
Promise Neuro-QOL
Description
The Patient Reported Outcomes Measurement Information System (PROMIS) Quality of Life in Neurological Disorders (Neuro-QoL) measurement system assesses health-related quality of life in neurological conditions. It includes questionnaires measuring physical function, mobility, emotional well-being, fatigue, social participation, and cognitive function. Scale titles vary by domain. Higher scores indicate better outcomes. T-scores facilitate interpretation and comparison. PROMIS Neuro-QOL provides insights for clinicians and researchers, addressing challenges in different functional domains of neurological conditions.
Time Frame
8 weeks
Title
SF-36
Description
The SF-36 is a self-reported questionnaire measuring health-related quality of life. It assesses dimensions like physical functioning, role limitations, pain, general health, vitality, social functioning, and mental health. It provides scores for each dimension and summary scores (PCS and MCS) for overall physical and mental health. Scale titles reflect specific dimensions. Scores range from 0 to 100, with higher scores indicating better health-related quality of life. SF-36 offers a comprehensive assessment of perceived health status and well-being.
Time Frame
8 weeks
Title
DKEFS Trails Making Test (Trails)
Description
Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test (Trails) measures visual attention and task-switching abilities. Part A involves connecting numbered circles, and Part B requires switching between numbers and letters. Completion time is the basis for scoring, with shorter times indicating better performance in visual attention and task-switching.
Time Frame
8 weeks
Title
DKEFS Verbal Learning Test (VLT)
Description
Delis-Kaplan Executive Function System (D-KEFS) Verbal Learning Test (VLT) evaluates verbal memory capabilities. Participants recall words across multiple trials, and the score is based on the number of correctly recalled words. Higher scores indicate superior verbal memory performance.
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age between 35 and 80 years no walking aids stable medication 4 weeks prior to and during the study no falls in the past 6 months participant must have MD who is willing to provide oversight and approval for clinically defined "off" state Exclusion Criteria: mild cognitive impairment (MoCA <25) self reported depression antidepressive or antipsychotic medication participation in a VNS study in the past year disabling bradykinesia to ensure patients are able to participate in intensive physiotherapy (based on clinical impression and in accordance to UPDRS part III item 14 - to be administered in clinic) prior history of cardiovascular, neurological or musculoskeletal disorders known to interfere with testing PD features implanted medical device of any type history of seizures peripheral neuropathy including temporal mandibular disorders and Bells Palsy, and vasovagal syncope.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandra Evancho, DPT
Phone
2054476846
Email
amelgin@uab.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Wendy Reed, PhD
Phone
2055154726
Email
wend@uab.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandra Evancho, DPT
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
WHARF
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecca Rogers, MS
Phone
205-975-5221
Email
rrrogers@uab.edu
First Name & Middle Initial & Last Name & Degree
Alexandra Evancho, DPT
First Name & Middle Initial & Last Name & Degree
Wendy Reed, PhD
First Name & Middle Initial & Last Name & Degree
Jennifer Dawson, DPT
First Name & Middle Initial & Last Name & Degree
Rebecca Rogers, MS
First Name & Middle Initial & Last Name & Degree
Marie Blair, MS
Facility Name
UAB
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra Evancho, DPT
Phone
205-447-6846
First Name & Middle Initial & Last Name & Degree
Alexandra Evancho, DPT
First Name & Middle Initial & Last Name & Degree
Wendy Reed, PhD
First Name & Middle Initial & Last Name & Degree
Jennifer Dawson, DPT
First Name & Middle Initial & Last Name & Degree
Lillie Garrett

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Combining VNS With PT Interventions for Individuals With PD

We'll reach out to this number within 24 hrs